Acute intravenous injection toxicity of BMEDA in mice

Drug and Chemical Toxicology

Volumn 34, Issue 1, 2011, Pages 20-24

  Chang, Chih Hsien ^a   Chiu, Shu Pei ^a   Chiang, Tung Chuan ^a   Lee, Te Wei ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

188Re BMEDA; 188Re BMEDA liposome; Acute toxicity; Radiopharmaceutical; Radiotherapy

Indexed keywords

LIPOSOME; N,N BIS(2 MERCAPTOETHYL) N',N' DIETHYLETHYLENEDIAMINE LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOOD INTAKE; LETHAL DOSE; MALE; MORTALITY; NONHUMAN; REGULATOR GENE; WEIGHT GAIN;

ACUTE TOXICITY TESTS; ANIMALS; ETHYLENEDIAMINES; FEMALE; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; LIPOSOMES; MALE; MICE; MICE, INBRED ICR; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS;

MUS; RODENTIA;

EID: 78649962948     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2010.482588     Document Type: Article

References (21)

1. 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44:1992-1999.
2. 99mTc- SNS/S complexes: in vitro and in vivo evaluation. J Pharm Sci 92:1893-1904.
3. 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and noninvasive imaging studies. J Pharmacol Exp Ther 308:419-425.
4. CDER. (1996). Single dose and repeat dose toxicity tests. Washington, DC: Center for Drug Evaluation and Research (CDER).
5. 188Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm 23:749-758.
6. 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol (In press).
7. 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 27:2217-2225.
8. 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34:415-423.
9. 188Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 35:883-893.
10. 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res (In press).
11. 2+ core. Inorg Chim Acta 90:41-51.
12. Emfietzoglou, D., Kostarelos, K., Sgouros, G. (2001). An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 42:499-504.
13. Hamoudeh, M., Kamleh, M. A., Diab, R., Fessi, H. (2008). Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60:1329-1346.
14. Haran, G., Cohen, R., Bar, L. K., Barenholz, Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201-215.
15. Marzin, D. (1998). Preclinical evaluation of radiopharmaceutical toxicological prerequisites. Nucl Med Biol 25:733-736.
16. Mitra, A., Nan, A., Line, B. R., Ghandehari, H. (2006). Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm des 12:4729-4749.
17. 186Re-Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging, and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol 36:515-524.
18. Ting, G., Chang, C. H., Wang, H. E. (2009). Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res 29:4107-4118.
19. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
20. 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 14:3975-3983.
21. 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Targ 16:626-637.